US Alzheimer's Disease Diagnostic Market Research Report Forecast to 2040

US Alzheimer's Disease Diagnostic market is anticipated to register a notable CAGR of 7.92% during the review period. Alzheimer's disease, often referred to simply as Alzheimer's, is a progressive and degenerative brain disorder that primarily affects cognitive functions, especially memory, thinking, and behavior. It is the most common cause of dementia in older adults. The disease is characterized by the accumulation of abnormal protein deposits, including beta-amyloid plaques and tau tangles, in the brain, which lead to the death of brain cells and the disruption of neural pathways.

The US Alzheimer's disease diagnostic market is emerging due to Increasing prevalence of Alzheimer's disease, growing aging population and raising awareness about Alzheimer's disease. Additionally, growth of telemedicine and remote monitoring technologies presents opportunities for Alzheimer's disease diagnostics market in the future. However, the high cost of diagnosis might hamper the market's growth in the forecast period.

Market Segmentation

Based on product, the market has been segmented into reagents & kits and equipment & accessories.

Based on the type, the market has been segmented into early onset Alzheimer disease and late onset Alzheimer disease.

Based on test type, the US Alzheimer's disease diagnostic market has been segmented into genetic testing, brain imaging, neurological exams, mini mental state exam (MMSE), and others.

Based on end user, the US Alzheimer's disease diagnostic market has been segmented into hospitals, and diagnostic laboratories, and others.

Major Players

The Key market players in the US Alzheimer's Disease Diagnostic market are Siemens, F. Hoffmann-La Roche Ltd, GE Healthcare, Fujirebio, QYNAPSE, and Koninklijke Philips N.V.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF ALZHEIMER'S DISEASE
- 4.2.2 GROWING AGING POPULATION
- 4.2.3 RAISING AWARENESS ABOUT ALZHEIMER'S DISEASE
4.3 RESTRAINTS
- 4.3.1 HIGH COST OF DIAGNOSIS
4.4 OPPORTUNITY
- 4.4.1 GROWTH OF TELEMEDICINE AND REMOTE MONITORING TECHNOLOGIES PRESENTS OPPORTUNITIES FOR ALZHEIMER'S DISEASE DIAGNOSTICS MARKET

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D AND DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION, MARKETING, AND SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 BARGAINING POWER OF SUPPLIERS
- 5.2.2 BARGAINING POWER OF BUYERS
- 5.2.3 THREAT OF NEW ENTRANTS
- 5.2.4 THREAT OF SUBSTITUTES
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT ANALYSIS OF COVID-19 ON ALZHEIMER'S DISEASE DIAGNOSTIC MARKET
- 5.3.1 OVERVIEW
5.4 MARKET KEY TRENDS FOR ALZHEIMER'S DISEASE DIAGNOSTIC MARKET
5.5 ANALYSIS OF INTELLECTUAL PROPERTY (IP) & STARTUPS
- 5.5.1 INTELLECTUAL PROPERTY (IP)
- 5.5.2 STARTUPS
5.6 CHANGES IN HEALTHCARE POLICIES
5.7 CLINICAL DIAGNOSIS OF ALZHEIMER'S DISEASE
5.8 PROVIDER AND PAYER COVERAGE POLICIES FOR ALZHEIMER'S DISEASE DIAGNOSTICS
5.9 ALZHEIMER'S DISEASE PRE-DIAGNOSIS AND DIAGNOSIS IN THE US
5.10 ALZHEIMER'S DISEASE TREATMENT/ DISEASE MANAGEMENT AND MONITORING

6 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY PRODUCT

6.1 OVERVIEW

7 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY TYPE

7.1 OVERVIEW

8 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY TEST TYPE

8.1 OVERVIEW

9 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY END USER

9.1 OVERVIEW

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2022
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 10.6.1 PARTNERSHIP

11 COMPANY PROFILES

11.1 SIEMENS
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 F. HOFFMANN-LA ROCHE LTD
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 GE HEALTHCARE
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
11.4 KONINKLIJKE PHILIPS N.V.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
11.5 BMG LABTECH
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
11.6 BIOASSAY SYSTEMS
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 SCIENCELL RESEARCH LABORATORIES, INC
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 KEY STRATEGIES
11.8 FUJIREBIO
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 KEY STRATEGIES
11.9 QUANTERIX
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
11.10 QYNAPSE
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES

12 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 29
TABLE 2 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2019-2040 (USD MILLION) 49
TABLE 3 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY TYPE, 2019-2040 (USD MILLION) 52
TABLE 4 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY TEST TYPE, 2019-2040 (USD MILLION) 56
TABLE 5 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, FOR BRAIN IMAGING, BY TYPE, 2019-2040 (USD MILLION) 56
TABLE 6 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY END USER, 2019-2040 (USD MILLION) 59
TABLE 7 PUBLIC PLAYERS STOCK SUMMARY 65
TABLE 8 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 65
TABLE 9 PRODUCT LAUNCH/PRODUCT APPROVAL 66
TABLE 10 PARTNERSHIP 66
TABLE 11 SIEMENS: PRODUCTS OFFERED 69
TABLE 12 SIEMENS: KEY DEVELOPMENTS 70
TABLE 13 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 73
TABLE 14 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 74
TABLE 15 GE HEALTHCARE: PRODCUTS OFFERED 77
TABLE 16 KONINKLIJKE PHILIPS N.V.: PRODCUTS OFFERED 81
TABLE 17 KONINKLIJKE PHILIPS N.V.: KEY DEVELOPMENTS 82
TABLE 18 BMG LABTECH: PRODCUTS OFFERED 84
TABLE 19 BIOASSAY SYSTEMS: PRODUCTS OFFERED 86
TABLE 20 SCIENCELL RESEARCH LABORATORIES, INC: PRODUCTS OFFERED 88
TABLE 21 FUJIREBIO: PRODCUTS OFFERED 90
TABLE 22 FUJIREBIO: KEY DEVELOPMENTS 91
TABLE 23 QUANTERIX: PRODCUTS OFFERED 92
TABLE 24 QYNAPSE: PRODCUTS OFFERED 94
TABLE 25 QYNAPSE: KEY DEVELOPMENTS 95

LIST OF FIGURES

FIGURE 1 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET: STRUCTURE 17
FIGURE 2 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 33
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2040) 35
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 36
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET 40
FIGURE 6 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, PRODUCT SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 48
FIGURE 7 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2022 & 2040 (USD MILLION) 49
FIGURE 8 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET SHARE (%), BY PRODUCT, 2022 50
FIGURE 9 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, TYPE SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 51
FIGURE 10 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY TYPE, 2022 & 2040 (USD MILLION) 52
FIGURE 11 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET SHARE (%), BY TYPE, 2022 53
FIGURE 12 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, TEST TYPE, SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 55
FIGURE 13 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY TEST TYPE, 2022 & 2040 (USD MILLION) 55
FIGURE 14 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET SHARE (%), BY TEST TYPE, 2022 57
FIGURE 15 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, END USER SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 58
FIGURE 16 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET, BY END USER, 2022 & 2040 (USD MILLION) 59
FIGURE 17 US ALZHEIMER'S DISEASE DIAGNOSTIC MARKET SHARE (%), BY END USER, 2022 60
FIGURE 18 US ALZHEIMER'S DISEASE DIAGNOSTICS MARKET PLAYERS: COMPETITIVE ANALSIS, 2022 63
FIGURE 19 COMPETITOR DASHBOARD: US ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 64
FIGURE 20 SIEMENS: FINANCIAL OVERVIEW SNAPSHOT 68
FIGURE 21 SIEMENS: SWOT ANALYSIS 70
FIGURE 22 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 73
FIGURE 23 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 74
FIGURE 24 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT 77
FIGURE 25 GE HEALTHCARE: SWOT ANALYSIS 78
FIGURE 26 KONINKLIJKE PHILIPS N.V.: FINANCIAL OVERVIEW SNAPSHOT 81
FIGURE 27 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS 83
FIGURE 28 BIOASSAY SYSTEMS: SWOT ANALYSIS 87